Glipizide extended-release tablets, 2.5mg, 30-count bottle, Rx Only, Manufactured By Patheon Ph...

FDA Drug Recall #D-0476-2017 — Class II — January 30, 2017

Recall Summary

Recall Number D-0476-2017
Classification Class II — Moderate risk
Date Initiated January 30, 2017
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Actavis Inc
Location Parsippany, NJ
Product Type Drugs
Quantity 499320 units

Product Description

Glipizide extended-release tablets, 2.5mg, 30-count bottle, Rx Only, Manufactured By Patheon Pharmaceuticals Inc Cincinnati OH 45237 USA, NDC 0591-0900-30, UPC 3-0591090030-4

Reason for Recall

Failed Dissolution Specifications. Above out of specification for dissolution rate observed at the 10 hour testing point.

Distribution Pattern

Nationwide in US

Lot / Code Information

Lot #: 3134201, 3134202, Exp. 06/30/17; 3134319, Exp. 05/31/17; 3135246, Exp. 07/31/17; 3135247, 3136781, Exp. 08/31/17; 3136782, Exp. 09/30/17; 3136903, 3136904, Exp.10/31/17; 3138250, Exp. 07/31/17; 3138968, Exp. 08/31/17; 3140000, Exp. 09/30/17

Other Recalls from Actavis Inc

Recall # Classification Product Date
D-0514-2017 Class III Levofloxacin Ophthalmic Solution, 0.5%, Sterile... Feb 7, 2017
D-0439-2017 Class III Albuterol Sulfate Inhalation Solution, USP, 0.0... Jan 12, 2017
D-1471-2016 Class III Acetasol HC (hydrocortisone and acetic acid oti... Aug 2, 2016
D-1472-2016 Class III Hydrocortisone and acetic acid otic solution, R... Aug 2, 2016
D-1448-2016 Class II Dextroamphetamine Sulfate Extended-Release Caps... Jul 11, 2016

Frequently Asked Questions

Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.